巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Corbus Pharmaceuticals Holdings

    CRBP
    0.170
    0.010
    5.56%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Corbus Pharmaceuticals Holdings - 延遲價格・最後更新於 23/09 12:00
    最高位
    0.181
    最低位
    0.170
    開市價
    --
    前收市價
    0.180
    成交量(千)
    12.35
    成交額(百萬)
    0.02
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    21.30
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    1.110 - 0.170
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Corbus Pharmaceuticals Holdings
    證券代碼
    CRBP.US
    所屬板塊
    Biotechnology
    公司業務
    Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
    發行量
    125243381
    公司總部
    500 River Ridge Drive, Second Floor
    公司網址
    https://www.corbuspharma.com
    公司電郵
    ir@corbuspharma.com
    公司電話
    +1 617 963-0100
    暫無內容

    關於

    Corbus Pharmaceuticals Holdings(CRBP.US)所屬的行業板塊為Biotechnology。
    Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
    詳細公司背景可參考: https://www.corbuspharma.com